Drug Type Bispecific T-cell Engager (BiTE) |
Synonyms |
Target |
Mechanism CD3 inhibitors(T cell surface glycoprotein CD3 inhibitors), ETA antagonists(Endothelin receptor type A antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseIND Application |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Ovarian Cancer | IND Application | CN | 27 Aug 2024 | |
Prostatic Cancer | IND Application | CN | 27 Aug 2024 | |
Triple Negative Breast Cancer | IND Application | CN | 27 Aug 2024 |